Historical Valuation
Minerva Neurosciences Inc (NERV) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.91. The fair price of Minerva Neurosciences Inc (NERV) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：4.45
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Minerva Neurosciences Inc (NERV) has a current Price-to-Book (P/B) ratio of -0.79. Compared to its 3-year average P/B ratio of -1.17 , the current P/B ratio is approximately -32.51% higher. Relative to its 5-year average P/B ratio of -1.82, the current P/B ratio is about -56.39% higher. Minerva Neurosciences Inc (NERV) has a Forward Free Cash Flow (FCF) yield of approximately -51.79%. Compared to its 3-year average FCF yield of -101.65%, the current FCF yield is approximately -49.05% lower. Relative to its 5-year average FCF yield of -91.56% , the current FCF yield is about -43.44% lower.
P/B
Median3y
-1.17
Median5y
-1.82
FCF Yield
Median3y
-101.65
Median5y
-91.56
Competitors Valuation Multiple
AI Analysis for NERV
The average P/S ratio for NERV competitors is 1.82, providing a benchmark for relative valuation. Minerva Neurosciences Inc Corp (NERV.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for NERV
1Y
3Y
5Y
Market capitalization of NERV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NERV in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NERV currently overvalued or undervalued?
Minerva Neurosciences Inc (NERV) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.91. The fair price of Minerva Neurosciences Inc (NERV) is between NaN to NaN according to relative valuation methord.
What is Minerva Neurosciences Inc (NERV) fair value?
NERV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Minerva Neurosciences Inc (NERV) is between NaN to NaN according to relative valuation methord.
How does NERV's valuation metrics compare to the industry average?
The average P/S ratio for NERV's competitors is 1.82, providing a benchmark for relative valuation. Minerva Neurosciences Inc Corp (NERV) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Minerva Neurosciences Inc (NERV) as of Jan 10 2026?
As of Jan 10 2026, Minerva Neurosciences Inc (NERV) has a P/B ratio of -0.79. This indicates that the market values NERV at -0.79 times its book value.
What is the current FCF Yield for Minerva Neurosciences Inc (NERV) as of Jan 10 2026?
As of Jan 10 2026, Minerva Neurosciences Inc (NERV) has a FCF Yield of -51.79%. This means that for every dollar of Minerva Neurosciences Inc’s market capitalization, the company generates -51.79 cents in free cash flow.
What is the current Forward P/E ratio for Minerva Neurosciences Inc (NERV) as of Jan 10 2026?
As of Jan 10 2026, Minerva Neurosciences Inc (NERV) has a Forward P/E ratio of -7.00. This means the market is willing to pay $-7.00 for every dollar of Minerva Neurosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Minerva Neurosciences Inc (NERV) as of Jan 10 2026?
As of Jan 10 2026, Minerva Neurosciences Inc (NERV) has a Forward P/S ratio of 0.00. This means the market is valuing NERV at $0.00 for every dollar of expected revenue over the next 12 months.